Revvity (RVTY) Financials: History & Chart

Revvity, Inc. (RVTY)RVTYRevvity, Inc.

About Revvity, Inc.

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.

Waltham, MA

11,000 employees

www.revvity.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Prahlad R. Singh

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Apr 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	2.90B	711.12M	772.06M	698.95M	720.28M	664.76M	N/A	729.37M	684.05M
Cost of Goods Sold	1.41B	323.46M	433.92M	324.35M	327.73M	289.22M	N/A	369.68M	299.23M
Gross Profit	1.49B	387.65M	338.14M	374.60M	392.56M	375.55M	N/A	359.69M	384.82M
Gross Profit Margin	51.4%	54.5%	43.8%	53.6%	54.5%	56.5%	N/A	49.3%	56.3%
Total Operating Expenses	1.13B	311.77M	226.39M	292.71M	301.80M	303.32M	N/A	227.40M	282.22M
Research & Development	220.13M	57.89M	58.18M	50.80M	53.27M	53.60M	N/A	49.21M	49.14M
Selling, General & Administrative	914.23M	253.88M	168.21M	241.91M	250.22M	249.72M	N/A	178.19M	233.07M
Operating Income (EBIT)	360.29M	75.89M	111.75M	81.90M	90.76M	72.23M	N/A	132.29M	102.60M
Operating Margin	12.4%	10.7%	14.5%	11.7%	12.6%	10.9%	N/A	18.1%	15.0%
Income Before Tax (EBT)	265.89M	49.99M	91.56M	55.69M	68.65M	52.38M	N/A	94.56M	100.36M
Interest Income	27.33M	6.30M	5.75M	6.92M	8.35M	10.08M	N/A	9.83M	22.76M
Interest Expense	93.94M	24.72M	23.51M	22.77M	22.94M	22.96M	N/A	22.78M	24.38M
Other Income/Expense	-94.40M	-25.89M	-20.19M	-26.21M	-22.11M	-19.85M	N/A	-37.73M	-2.24M
Net Income	240.96M	40.72M	98.36M	46.65M	55.22M	42.24M	88.38M	95.04M	93.97M
Income Tax Expense	24.19M	9.10M	-6.80M	8.46M	13.43M	10.71M	N/A	6.17M	6.97M
Net Profit Margin	8.3%	5.7%	12.7%	6.7%	7.7%	6.4%	N/A	13.0%	13.7%
EBITDA	773.26M	180.94M	214.83M	183.96M	193.54M	169.65M	N/A	237.32M	210.27M
EBITDA Margin	26.6%	25.4%	27.8%	26.3%	26.9%	25.5%	N/A	32.5%	30.7%
Depreciation & Amortization	412.97M	105.06M	103.08M	102.06M	102.78M	97.42M	105.03M	105.03M	107.67M
EPS Basic	2.10	0.36	0.87	0.40	0.47	0.34	N/A	0.78	0.77
EPS Diluted	2.10	0.36	0.87	0.40	0.47	0.34	N/A	0.78	0.76
Shares Outstanding	111.88M	111.88M	113.21M	117.73M	117.54M	120.14M	N/A	121.83M	122.81M
Diluted Shares Outstanding	111.88M	111.88M	113.21M	117.73M	117.54M	120.23M	N/A	121.58M	123.03M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/28/2025	12/29/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	2.86B	2.76B	2.75B	3.31B	3.83B	3.78B	2.88B	2.78B
Cost of Goods Sold	1.34B	1.43B	1.43B	1.55B	1.55B	1.79B	1.59B	1.53B
Gross Profit	1.52B	1.32B	1.32B	1.76B	2.28B	1.99B	1.29B	1.25B
Gross Profit Margin	53.1%	48.0%	48.1%	53.2%	59.6%	52.6%	44.8%	45.0%
Total Operating Expenses	1.16B	912.14M	922.70M	979.61M	941.95M	970.72M	887.57M	880.27M
Research & Development	215.84M	196.84M	216.58M	221.62M	200.34M	205.39M	189.34M	186.10M
Selling, General & Administrative	945.28M	715.30M	706.12M	757.99M	741.61M	765.33M	698.24M	694.17M
Operating Income (EBIT)	356.63M	410.52M	399.49M	781.12M	1.34B	1.02B	405.48M	370.97M
Operating Margin	12.5%	14.9%	14.5%	23.6%	35.0%	27.0%	14.1%	13.4%
Income Before Tax (EBT)	268.28M	316.13M	182.98M	651.84M	1.20B	906.36M	237.14M	257.68M
Interest Income	31.10M	73.19M	72.13M	3.59M	2.24M	1.01M	1.50M	1.14M
Interest Expense	92.19M	96.28M	98.81M	103.95M	102.13M	49.71M	63.63M	66.98M
Other Income/Expense	-88.36M	-94.39M	-216.51M	-129.28M	-136.42M	-113.43M	-168.34M	-113.28M
Net Income	241.68M	295.83M	-118.38M	569.18M	943.16M	728.10M	227.56M	238.79M
Income Tax Expense	25.80M	33.05M	3.47M	139.16M	314.15M	178.27M	9.39M	20.21M
Net Profit Margin	8.5%	10.7%	-4.3%	17.2%	24.6%	19.2%	7.9%	8.6%
EBITDA	658.90M	838.37M	831.26M	1.21B	1.65B	1.27B	619.51M	551.56M
EBITDA Margin	23.1%	30.4%	30.2%	36.5%	43.1%	33.5%	21.5%	19.9%
Depreciation & Amortization	302.26M	427.85M	431.77M	427.00M	311.44M	246.51M	214.03M	180.59M
EPS Basic	2.08	2.41	-0.95	4.51	8.12	6.53	2.05	2.16
EPS Diluted	2.08	2.41	-0.95	4.50	8.08	6.49	2.04	2.14
Shares Outstanding	113.21M	122.76M	124.70M	126.16M	116.17M	111.51M	110.83M	110.56M
Diluted Shares Outstanding	113.21M	122.82M	124.81M	126.43M	116.67M	112.08M	111.50M	111.53M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.